Wed, May 14, 11:07 AM (60 days ago)
**Unicycive Therapeutics, Inc. (UNCY) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** Not explicitly stated, implying minimal or no revenue. - **Profit Margins:** Net income of $0.6 million for Q1 2025, a significant improvement from a net loss of $20.9 million in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $8.9 million for Q1 2025, compared to $6.5 million in Q1 2024. - **Earnings Changes:** Significant improvement in net income, primarily due to changes in the fair value of warrant liability. **Quarterly Performance Discussion:** - **Operating Expenses:** Total operating expenses decreased by 13% to $7.9 million in Q1 2025 from $9.2 million in Q1 2024. - **Research & Development:** Expenses decreased by 68% to $2.2 million, primarily due to a $5.0 million reduction in drug development costs. - **General & Administrative:** Expenses increased by 143% to $5.8 million, mainly due to higher consulting and professional services related to commercial launch. - **Other Income/Expenses:** Significant increase of $20.3 million, primarily due to changes in the fair value of warrant liability. **Trends & Uncertainties:** - **Future Operations Impact:** Expects to continue incurring losses and requires additional capital to fund clinical trials and product development. - **Funding:** Plans to raise capital through equity offerings, debt financing, or corporate collaborations. - **Market Risks:** Dependence on successful development, regulatory approval, and commercialization of product candidates. **Key Metrics:** - **Cash Position:** $19.8 million in cash and cash equivalents as of March 31, 2025. - **Accumulated Deficit:** $100.7 million as of March 31, 2025. - **Stock Performance:** Nasdaq listing compliance extended to July 7, 2025, due to stock price below $1.00. **Future Outlook:** - **Funding Requirements:** Anticipates needing substantial additional capital to sustain operations and meet obligations through Q1 2026. - **Strategic Focus:** Continues to develop and commercialize therapies for kidney disease, with a focus on Oxylanthanum Carbonate and UNI-494.